{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:35Z","timestamp":1777374395866,"version":"3.51.4"},"reference-count":79,"publisher":"Impact Journals, LLC","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,3,30]]},"DOI":"10.18632\/oncotarget.24698","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T12:30:39Z","timestamp":1522413039000},"page":"16792-16806","source":"Crossref","is-referenced-by-count":22,"title":["STAT5 inhibition induces TRAIL\/DR4 dependent apoptosis in peripheral T-cell lymphoma"],"prefix":"10.18632","volume":"9","author":[{"given":"Haley M.","family":"Simpson","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Program in Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Furusawa","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Program in Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha","family":"Sadashivaiah","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Program in Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curt I.","family":"Civin","sequence":"additional","affiliation":[{"name":"Program in Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Department of Physiology and Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnob","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Program in Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12185-014-1521-2","article-title":"From empiric to mechanism-based therapy for peripheral T cell lymphoma","volume":"99","author":"Younes","year":"2014","journal-title":"Int J Hematol"},{"key":"2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"Tilly","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-016-0267-0","article-title":"Therapeutic options in peripheral T cell lymphoma","volume":"9","author":"Li","year":"2016","journal-title":"J Hematol Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1016\/j.bmcl.2014.08.046","article-title":"Selective inhibitors of the Janus kinase Jak3--Are they effective?","volume":"24","author":"Zerwes","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"5","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Tobinai","year":"2011","journal-title":"Blood"},{"key":"6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11899-011-0100-3","article-title":"Update: peripheral T-cell lymphomas","volume":"6","author":"Savage","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fonc.2013.00138","article-title":"Peripheral T-cell lymphomas: a review of current approaches and hopes for the future","volume":"3","author":"Pro","year":"2013","journal-title":"Front Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Edgren","year":"2012","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","article-title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas","volume":"120","author":"Eckloff","year":"2012","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia","volume":"120","author":"Hsi","year":"2012","journal-title":"Blood"},{"key":"11","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","article-title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia","volume":"121","author":"Ellonen","year":"2013","journal-title":"Blood"},{"key":"12","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type","volume":"115","author":"Emile","year":"2010","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1532\/ijh97.06165","article-title":"Detection of NOTCH1 mutations in adult T-cell leukemia\/lymphoma and peripheral T-cell lymphoma","volume":"85","author":"Taniwaki","year":"2007","journal-title":"Int J Hematol"},{"key":"14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Nicolas","year":"2014","journal-title":"Nat Genet"},{"key":"15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Medeiros","year":"2014","journal-title":"Blood"},{"key":"16","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1182\/blood-2014-02-555946","article-title":"The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature","volume":"123","author":"Rodriguez-Pinilla","year":"2014","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3324\/haematol.2014.113696","article-title":"Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas","volume":"100","author":"Perez-Seoane","year":"2015","journal-title":"Haematologica"},{"key":"18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3324\/haematol.2011.041921","article-title":"Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma","volume":"96","author":"Cools","year":"2011","journal-title":"Haematologica"},{"key":"19","doi-asserted-by":"publisher","first-page":"e109714","DOI":"10.1371\/journal.pone.0109714","article-title":"Detection of the G17V RHOA mutation in angioimmunoblastic T-cell lymphoma and related lymphomas using quantitative allele-specific PCR","volume":"9","author":"Yokoyama","year":"2014","journal-title":"PLoS One"},{"key":"20","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/leu.2014.200","article-title":"Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas","volume":"28","author":"Raffeld","year":"2014","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells","volume":"6","author":"Sen","year":"2015","journal-title":"Nat Commun"},{"key":"22","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome","volume":"6","author":"Kunkel","year":"2015","journal-title":"Nat Commun"},{"key":"23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/leu.2016.13","article-title":"JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma","volume":"30","author":"Pang","year":"2016","journal-title":"Leukemia"},{"key":"24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjh.13952","article-title":"Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia","volume":"173","author":"Campo","year":"2016","journal-title":"Br J Haematol"},{"key":"25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mce.2017.02.019","article-title":"JAK\/STAT pathway directed therapy of T-cell leukemia\/lymphoma: Inspired by functional and structural genomics","volume":"451","author":"Waldmann","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/jbm.s51253","article-title":"Profile of pacritinib and its potential in the treatment of hematologic disorders","volume":"5","author":"Briasoulis","year":"2014","journal-title":"J Blood Med"},{"key":"27","doi-asserted-by":"publisher","first-page":"24407","DOI":"10.1074\/jbc.M909771199","article-title":"Constitutive activation of STAT5 by a point mutation in the SH2 domain","volume":"275","author":"Kitamura","year":"2000","journal-title":"J Biol Chem"},{"key":"28","doi-asserted-by":"publisher","first-page":"e0141906","DOI":"10.1371\/journal.pone.0141906","article-title":"Concurrent Mutations in ATM and Genes Associated with Common gamma Chain Signaling in Peripheral T Cell Lymphoma","volume":"10","author":"Livak","year":"2015","journal-title":"PLoS One"},{"key":"29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jaut.2008.03.002","article-title":"The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2)","volume":"31","author":"Gershwin","year":"2008","journal-title":"J Autoimmun"},{"key":"30","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in cancer immunotherapy","volume":"3","author":"Margolin","year":"2011","journal-title":"Cancers (Basel)"},{"key":"31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy","volume":"35","author":"Chen","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.cd-12-0028","article-title":"Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma","volume":"2","author":"Yeoh","year":"2012","journal-title":"Cancer Discov"},{"key":"33","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1182\/blood-2014-04-566687","article-title":"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model","volume":"124","author":"Meijerink","year":"2014","journal-title":"Blood"},{"key":"34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/gcc.22141","article-title":"Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia","volume":"53","author":"Ammerpohl","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"35","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.3324\/haematol.2014.104992","article-title":"The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse","volume":"99","author":"Hof","year":"2014","journal-title":"Haematologica"},{"key":"36","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00277-015-2357-4","article-title":"Current and future treatment options for polycythemia vera","volume":"94","author":"Mesa","year":"2015","journal-title":"Ann Hematol"},{"key":"37","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJMc1400499","article-title":"JAK inhibitor in CALR-mutant myelofibrosis","volume":"370","author":"Kralovics","year":"2014","journal-title":"N Engl J Med"},{"key":"38","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Frank","year":"2011","journal-title":"Blood"},{"key":"39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/1947601912466555","article-title":"The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations","volume":"3","author":"Kung","year":"2012","journal-title":"Genes Cancer"},{"key":"40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V55.3.409.409","article-title":"Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas","volume":"55","author":"Guccion","year":"1980","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V70.4.1069.1069","article-title":"Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia\/lymphoma virus","volume":"70","author":"Uchino","year":"1987","journal-title":"Blood"},{"key":"42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jmi.12133","article-title":"Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques","volume":"255","author":"Rani","year":"2014","journal-title":"J Microsc"},{"key":"43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2184.2003.00283.x","article-title":"The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines","volume":"36","author":"Machalinski","year":"2003","journal-title":"Cell Prolif"},{"key":"44","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood.V98.9.2778","article-title":"Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells","volume":"98","author":"Dobbeling","year":"2001","journal-title":"Blood"},{"key":"45","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/1535-7163.mct-13-0341","article-title":"Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2","volume":"13","author":"Frank","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1749-6632.2010.05907.x","article-title":"The role of STAT5 in the development, function, and transformation of B and T lymphocytes","volume":"1217","author":"Farrar","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"47","doi-asserted-by":"publisher","first-page":"e86790","DOI":"10.1371\/journal.pone.0086790","article-title":"Identification of STAT5A and STAT5B target genes in human T cells","volume":"9","author":"Nadeau","year":"2014","journal-title":"PLoS One"},{"key":"48","unstructured":"Perez. Deathbase: Cell Death\/Apoptosis Database. 2017."},{"key":"49","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.molonc.2012.02.002","article-title":"Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling","volume":"6","author":"Jove","year":"2012","journal-title":"Mol Oncol"},{"key":"50","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/sj.onc.1202796","article-title":"IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line","volume":"18","author":"Gouilleux","year":"1999","journal-title":"Oncogene"},{"key":"51","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.4049\/jimmunol.164.5.2533","article-title":"The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5","volume":"164","author":"Nelson","year":"2000","journal-title":"J Immunol"},{"key":"52","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1038\/cddis.2012.171","article-title":"JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry","volume":"3","author":"Tzur","year":"2012","journal-title":"Cell Death Dis"},{"key":"53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcdb.2015.01.006","article-title":"Targeting extrinsic apoptosis in cancer: Challenges and opportunities","volume":"39","author":"Fulda","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cytogfr.2008.04.001","article-title":"Targeting the extrinsic apoptosis pathway in cancer","volume":"19","author":"Ashkenazi","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1044-579X(02)00131-1","article-title":"Cell surface Death Receptor signaling in normal and cancer cells","volume":"13","author":"El-Deiry","year":"2003","journal-title":"Semin Cancer Biol"},{"key":"56","doi-asserted-by":"publisher","first-page":"12480","DOI":"10.1073\/pnas.1516208112","article-title":"Selective targeting of JAK\/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia","volume":"112","author":"O'Shea","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"57","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.V126.23.2528.2528","article-title":"Inhibition of the JAK\/STAT and Bcl-2 Pathways Enhances Anti-Tumor Effects in an in vitro model of T-Cell Acute Lymphoblastic Leukemia (T-ALL)","volume":"126","author":"Capitini","year":"2015","journal-title":"Blood"},{"key":"58","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1158\/1535-7163.mct-13-0323","article-title":"APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors","volume":"12","author":"Hill","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"59","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1021\/ml500165r","article-title":"Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein","volume":"5","author":"Gunning","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"60","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/jco.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Walewski","year":"2015","journal-title":"J Clin Oncol"},{"key":"61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"9","author":"Coiffier","year":"2016","journal-title":"J Hematol Oncol"},{"key":"62","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/jco.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Shustov","year":"2014","journal-title":"J Clin Oncol"},{"key":"63","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/jco.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Kennedy","year":"2012","journal-title":"J Clin Oncol"},{"key":"64","doi-asserted-by":"publisher","first-page":"123756","DOI":"10.1155\/2015\/123756","article-title":"Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission","volume":"2015","author":"Dang","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"65","unstructured":"FDA. Current and Resolved Drug Shortages and Discontinuations Reported to FDA. 2014."},{"key":"66","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3109\/10428190903580402","article-title":"A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas","volume":"51","author":"Jager","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"67","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/jco.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Fujiwara","year":"2012","journal-title":"J Clin Oncol"},{"key":"68","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Reiman","year":"2010","journal-title":"Cancer"},{"key":"69","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Coiffier","year":"2013","journal-title":"Eur J Cancer"},{"key":"70","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Reiman","year":"2015","journal-title":"Cancer"},{"key":"71","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2013.271","article-title":"Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia","volume":"28","author":"Stern","year":"2014","journal-title":"Leukemia"},{"key":"72","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2012.03.017","article-title":"Janus kinase deregulation in leukemia and lymphoma","volume":"36","author":"Green","year":"2012","journal-title":"Immunity"},{"key":"73","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"Eischen","year":"2015","journal-title":"Blood"},{"key":"74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/leu.2013.157","article-title":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma","volume":"28","author":"Louache","year":"2014","journal-title":"Leukemia"},{"key":"75","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/leu.2009.91","article-title":"STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK\/T-cell lymphoma","volume":"23","author":"Lassoued","year":"2009","journal-title":"Leukemia"},{"key":"76","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1182\/blood-2010-09-305425","article-title":"CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM\/TSP","volume":"117","author":"Waldmann","year":"2011","journal-title":"Blood"},{"key":"77","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.onc.1205152","article-title":"Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death","volume":"21","author":"Inghirami","year":"2002","journal-title":"Oncogene"},{"key":"78","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol Res"},{"key":"79","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.sjbs.2017.01.034","article-title":"Optimizing conditions for calcium phosphate mediated transient transfection","volume":"24","author":"Ma","year":"2017","journal-title":"Saudi J Biol Sci"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T15:27:54Z","timestamp":1589038074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":79,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,3,30]]}},"alternative-id":["24698","29682185"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24698","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,30]]}}}